Neuropathy Less Severe, Frequent With Eribulin vs Paclitaxel

However, among patients with invasive breast cancer, pathologic complete response rates with eribulin were lower. The study was published as a preprint and has not yet been peer reviewed.
First Look

source https://www.medscape.com/viewarticle/968686?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?